Activity
-
Very good article in the Financial Times with fantastic graphics about CAR T-cell therapy and the story of the world's 3rd patient with lupus who…
Very good article in the Financial Times with fantastic graphics about CAR T-cell therapy and the story of the world's 3rd patient with lupus who…
Liked by Jay Fine
-
Mama’s budding little scientist 👩🔬 🥰 #snailresearch
Mama’s budding little scientist 👩🔬 🥰 #snailresearch
Liked by Jay Fine
-
Today’s article is part of the motivation series. Few things are more motivating than progress, and the progress the Hispanic community has made in…
Today’s article is part of the motivation series. Few things are more motivating than progress, and the progress the Hispanic community has made in…
Liked by Jay Fine
Experience & Education
More activity by Jay
-
🇩🇪 🚀 Big financing round for a pretty unique biopharma story. ⬇ It was a pleasure to support the SciRhom team with communicating their EUR 63 M…
🇩🇪 🚀 Big financing round for a pretty unique biopharma story. ⬇ It was a pleasure to support the SciRhom team with communicating their EUR 63 M…
Liked by Jay Fine
-
Excited to announce our $7.14M seed round at Granza Bio (YC W24) led by Felicis and Refactor! We’re revolutionising the way we deliver therapeutic…
Excited to announce our $7.14M seed round at Granza Bio (YC W24) led by Felicis and Refactor! We’re revolutionising the way we deliver therapeutic…
Liked by Jay Fine
-
Congratulations Ashwin Jainarayanan and Ashwin Menon Nandakumar! So exciting to be supporting Granza Bio (YC W24).
Congratulations Ashwin Jainarayanan and Ashwin Menon Nandakumar! So exciting to be supporting Granza Bio (YC W24).
Liked by Jay Fine
-
We are delighted to announce the appointments of Adrian Ray and Scott Turner as Scientific Advisors. Dr Giuseppe Mazza CEO said: “We are pleased to…
We are delighted to announce the appointments of Adrian Ray and Scott Turner as Scientific Advisors. Dr Giuseppe Mazza CEO said: “We are pleased to…
Liked by Jay Fine
-
Mazen Noureddin, MD, MHSc presents about Rezdiffra for MASH treatment (F2/F3) this morning at the American Diabetes Association conference. “I have…
Mazen Noureddin, MD, MHSc presents about Rezdiffra for MASH treatment (F2/F3) this morning at the American Diabetes Association conference. “I have…
Liked by Jay Fine
-
Thanks everyone for a fantastic experience.
Thanks everyone for a fantastic experience.
Shared by Jay Fine
-
I’m humbled and thrilled to join the board at Nkarta with such an outstanding management team and Board. As a rheumatologist, I’m excited by the…
I’m humbled and thrilled to join the board at Nkarta with such an outstanding management team and Board. As a rheumatologist, I’m excited by the…
Liked by Jay Fine
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Jay Fine in United States
22 others named Jay Fine in United States are on LinkedIn
See others named Jay Fine